Work

Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study

Year: 2006

Type: article

Study design: Clinical Trial

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-05-2379

Authors: George R. Simon, Christopher R. Garrett, Stephen C. Olson, Michael Langevin, Irene A. Eiseman, John J. Mahany, Charles C. Williams, Richard Lush, Adil Daud, Pamela Munster, Alberto Chiappori, Mayer Fishman, Gerold Bepler, Peter F. Lenehan, Daniel M. Sullivan

Institutions: Moffitt Cancer Center, University of South Florida, Pfizer (United States)

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2099245955

FWCI: 2.253

Cites: 31

Cited by: 32

Related to: 10